Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 9/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.33 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | VSIR | Q9H7M9 | 1/20 | 0.33 |
| ▸ | CD274 | Q9NZQ7 | 4/20 | 0.32 |
| ▸ | PDCD1 | Q15116 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5226736 | 0.90 | KCNH2 (0.50) | P2RX7KCNH2CD274PDCD1 | |
| SCHEMBL5229626 | 0.81 | HTT (0.39) | P2RX7KCNH2 | |
| SCHEMBL10254128 | 0.78 | P2RX7 (0.41) | P2RX7KCNH2MAPT | |
| SCHEMBL5228520 | 0.78 | ALDH1A1 (0.39) | P2RX7KCNH2MAPT | |
| SCHEMBL5224371 | 0.78 | KCNH2 (0.44) | P2RX7KCNH2MAPTCD274 | |
| SCHEMBL508731 | 0.76 | P2RX7 (0.41) | P2RX7KCNH2MAPT | |
| SCHEMBL5226230 | 0.74 | P2RX7 (0.62) | P2RX7MAPT | |
| SCHEMBL509432 | 0.74 | BCHE (0.40) | MAPTPOLB | |
| SCHEMBL509008 | 0.74 | LMNA (0.38) | P2RX7KCNH2CARM1PRMT6MAPT | |
| SCHEMBL508948 | 0.73 | KCNH2 (0.44) | P2RX7KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1377556-B1 | PYRAZOLE DERIVATIVES FOR TREATING HIV | PFIZER LTD (GB) | 2007-04-04 | — | — | EP | claimed |
| EP-1762567-A1 | Pyrazole derivatives for treating HIV | Pfizer Limited (GB) | 2007-03-14 | — | — | EP | claimed |
| EP-1377556-A1 | PYRAZOLE DERIVATIVES FOR TREATING HIV | Pfizer Limited (GB) | 2004-01-07 | — | — | EP | claimed |
| US-20030100554-A1 | Pyrazole derivatives | JONES LYN HOWARD (GB) | 2003-05-29 | — | — | US | claimed |
| WO-2002085860-A1 | PYRAZOLE DERIVATIVES FOR TREATING HIV | PFIZER LIMITED (GB) | 2002-10-31 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100554-A1 | Pyrazole derivatives | REV1, SARS1, CYP2F1 | P2RX7 2065/4885KCNH2 3503/4885CNR1 3071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.